RxDoctor Payments Data

Stacie Kregel

Family · Sylvania, OHNPI 1851789895

Payments from drug & device makers

$7,770in general payments, 2019–2025

Across 382 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • Inspire Medical Systems, Inc.$720
  • Boehringer Ingelheim$469
  • Sanofi$387
  • United Therapeutics Corporation$334
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$5297%
  • Food & beverage$6,93989%
  • Education$3024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,770 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$70,249
Medicare patients
482
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter220$173,764
Breo ElliptaFluticasone/Vilanterol239$103,417
Spiriva RespimatTiotropium Bromide81$49,101
Incruse ElliptaUmeclidinium Bromide98$37,204
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$37,181
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$30,345
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate108$22,011
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$12,346
Arnuity ElliptaFluticasone Furoate29$7,851
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$5,932
Roflumilast68$5,782
Advair HfaFluticasone Propion/Salmeterol11$4,998
SymbicortBudesonide/Formoterol Fumarate15$4,733
Albuterol Sulfate HfaAlbuterol Sulfate198$4,578
Wixela InhubFluticasone Propion/Salmeterol22$2,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$1,265$359,417660 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$469$61,44798 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,207$35,07863 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →